Results 91 to 100 of about 785,489 (353)

Somatic ERK activation during transit amplification is essential for maintaining the synchrony of germline divisions in Drosophila testis [PDF]

Open Biology, 2018
Transit amplification (TA) of progenitor cells maintains tissue homeostasis by balancing proliferation and differentiation. In Drosophila testis, the germline proliferation is tightly regulated by factors present in both the germline and the neighbouring
Samir Gupta, Bhavana Varshney, Shambhabi Chatterjee, Krishanu Ray   +3 more
doaj   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

Molecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son, Lily L. Remsing Rix, Bin Fang, Eric A. Welsh, Nicole V. Bremer, Valentina Foglizzo, Paola Roa, Nickole Sigcha‐Coello, Yi Liao, Eric B. Haura, Alexander Drilon, John M. Koomen, Emiliano Cocco, Uwe Rix   +13 more
wiley   +1 more source

Obstetric and long-term kidney outcomes in renal transplant recipients: a 40 year single-centre study [PDF]

, 2016
Female renal transplant recipients of childbearing age may ask what the outcomes are for pregnancy and whether pregnancy will affect graft function. We analyzed obstetric and transplant outcomes among renal transplant recipients in our center who have ...
Brennand, Janet E., Deighan, Christopher J., Geddes, Colin C., Gorrie, Morag, Mark, Patrick B., McNeill, Susan H., Stoumpos, Sokratis   +6 more
core   +1 more source

Molecular characterisation of human penile carcinoma and generation of paired epithelial primary cell lines

Molecular Oncology, EarlyView.
Generation of two normal and tumour (cancerous) paired human cell lines using an established tissue culture technique and their characterisation is described. Cell lines were characterised at cellular, protein, chromosome and gene expression levels and for HPV status.
Simon Broad, Mahmood Hachim, Tom Bertin, Karolina Penderecka, Rifat Hamoudi, Saif Khan, Rui Henrique, Natalie Bergmoser, Manit Arya, Kalle Sipila, Matteo Vietri Rudan, Asif Muneer, Aamir Ahmed   +12 more
wiley   +1 more source

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer

Clinical Cancer Research, 2020
Purpose: The impact of EGFR tyrosine kinase inhibitors (TKI) on the tumor immune microenvironment (TME) in non–small cell lung cancer (NSCLC) is unclear.
K. Isomoto, K. Haratani, H. Hayashi, S. Shimizu, S. Tomida, T. Niwa, T. Yokoyama, Y. Fukuda, Y. Chiba, R. Kato, J. Tanizaki, Kaoru Tanaka, M. Takeda, T. Ogura, T. Ishida, Akihiko Ito, K. Nakagawa   +16 more
semanticscholar   +1 more source

Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. [PDF]

, 2017
Cross-talk among oncogenic signaling and metabolic pathways may create opportunities for new therapeutic strategies in cancer. Here we show that although acute inhibition of EGFR-driven glucose metabolism induces only minimal cell death, it lowers the ...
A Magi, AM Spence, Anthony Letai, AV Follis, AV Vaseva, BA Tannous, BJ Altman, Brian Higgins, C Tovar, CW Brennan, D Jiang, D Nathanson, DA Nathanson, DA Reardon, David A Nathanson, DR Green, E Cerami, E Strom, E Tasdemir, EH Cheng, EQ Lee, G Lessene, H Dai, H Takanaga, Harley I Kornblum, I Babic, I Vivanco, J Deng, J Gao, J Lee, J Lehár, J Montero, J Pomerantz, Jason T Lee, JC Liu, JE Chipuk, JE Chipuk, JE Chipuk, JIJ Leu, Jonathan E Tsang, JP Kruse, K Masui, L Qu, Laura Gosa, Lisa Ta, M Mihara, M-K Han, MG Vander Heiden, Mitra Dehghan Harati, MJ Lee, Nicholas A Bayley, OD Maddocks, P Nagesh Rao, Paul S Mischel, Peter M Clark, PM Clark, PY Wen, Q Ding, R Haq, RGW Verhaak, RJ DeBerardinis, Steven J Bensinger, TF Cloughesy, Timothy F Cloughesy, Veerle W Daniels, W Blake Gilmore, W Wei, WH Yang, William H Yong, Wilson X Mai, Y Zhang, Y Zhao   +71 more
core   +1 more source

Strength through diversity: how cancers thrive when clones cooperate

Molecular Oncology, EarlyView.
Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken, Maartje Witsen, Emile E. Voest, Krijn K. Dijkstra   +3 more
wiley   +1 more source

Gefitinib effectively treated advanced lung cancer with a rare EGFR L747P mutation in a kidney transplant recipient: the first case report [PDF]

, 2023
Wenxiu Xie, Feng Chen, Zhang Lei, Baoquan Lin, Jia Ye, Zongyang Yu, Wei Liu   +6 more
openalex   +1 more source

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

JAMA Oncology, 2018
Importance Osimertinib mesylate is used globally to treat EGFR-mutant non–small cell lung cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by the EGFR T790M mutation.
G. Oxnard, Yuebi Hu, K. Mileham, H. Husain, D. Costa, P. Tracy, N. Feeney, L. Sholl, S. Dahlberg, A. Redig, D. Kwiatkowski, M. Rabin, C. Paweletz, K. Thress, P. Jänne   +14 more
semanticscholar   +1 more source

Dual targeting of EGFR and glutaminase in lung cancer

Molecular & Cellular Oncology, 2018
We have recently demonstrated that targeted inhibition of epidermal growth factor receptor (EGFR) signaling and glutaminase led to metabolic crisis in EGFR mutant lung adenocarcinomas and significant tumor regression in mouse xenograft models.
Milica Momcilovic, David B. Shackelford
doaj   +1 more source